We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Pharmacokinetics of Resveratrol Comprising Products

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: December 11, 2012
Last Update Posted: May 3, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Fruitura Bioscience Ltd.
This study was designed to assess the pharmacokinetics of 2 doses of Red Grape Cells (RGC) containing resveratrol compared with a reference. RGC will be administered as single oral dose to fasting healthy volunteers. Plasma concentration of free resveratrol and total conjugates will be analyzed.

Condition Intervention
Healthy Dietary Supplement: RGC Dietary Supplement: Resveratrol

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Official Title: Randomized Three-way Cross-over Comparative Pharmacokinetic Study of Resveratrol Comprising Products in Fasting Healthy Subjects

Resource links provided by NLM:

Further study details as provided by Fruitura Bioscience Ltd.:

Primary Outcome Measures:
  • Individual plasma concentrations of free and conjugated resveratrol [ Time Frame: 24 hours ]
    Pharmacokinetic data such as the peak plasma concentration (Cmax), time to peak (Tmax) ans area under the concentration-time curves (AUCt) will be reported.

Enrollment: 15
Study Start Date: August 2012
Study Completion Date: March 2013
Primary Completion Date: October 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: RGC1
RGC containing the equivalent of 50 mg resveratrol
Dietary Supplement: RGC
Active Comparator: Resveratrol
The equivalent of 150 mg resveratrol
Dietary Supplement: Resveratrol
The equivalent of 150 mg resveratrol
Other Name: Transmax (Biotivia Ltd.)
Experimental: RGC2
RGC containing the equivalent of 150 mg resveratrol
Dietary Supplement: RGC


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Ages 18-55 years;
  • BMI >/= 19 and </= 30
  • non smoking
  • without history or evidence of significant cardiovascular, hepatic, renal, respiratory, gastrointestinal disease
  • normal physical and laboratory examinations

Exclusion Criteria:

  • History or evidence of alcohol or drug abuse
  • subjects receiving chronic medication
  • unusual dietary habits or a recent change in body weight
  • acute medical situation 48 hours prior to initiation of the study
  • poor venous access
  • Subjects participated in a trial or donated blood within 4 weeks before initiation of the study
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01747252

BioStudies Center
Beer-Sheva, Israel, 84101
Sponsors and Collaborators
Fruitura Bioscience Ltd.
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Fruitura Bioscience Ltd.
ClinicalTrials.gov Identifier: NCT01747252     History of Changes
Other Study ID Numbers: 08/12
First Submitted: December 9, 2012
First Posted: December 11, 2012
Last Update Posted: May 3, 2013
Last Verified: May 2013

Additional relevant MeSH terms:
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Molecular Mechanisms of Pharmacological Action
Protective Agents
Enzyme Inhibitors
Platelet Aggregation Inhibitors
Antimutagenic Agents
Anticarcinogenic Agents